Grimshaw

Document Sample
Grimshaw Powered By Docstoc
					    Macromolecular Crystallization and Structural Analysis at ESBATech

       P. Richle1, B. Blattmann2, D. Urech1, M. Grütter2, J.P.A. Grimshaw1
            1
           ESBATech AG, Wagistrasse 21, 8952 Zürich-Schlieren
2
Biochemisches Institut, Universität Zürich, Winterthurerstrasse 190, 8057 Zürich

                       John.Grimshaw@ESBATech.com



Abstract:

ESBATech AG is a clinical-stage biotechnology company that is developing a
pipeline of proprietary single-chain antibody fragment therapeutics for topical and
local delivery, particularly suited to treat eye diseases. These therapeutics have the
potential to deliver therapies with superior efficacy and safety relative to existing
approaches. ESBATech has advanced its antibody fragment technology to preclinical
and clinical stages in the eye for various diseases, including age-related macular
degeneration, diabetic macular edema, glaucoma, dry eye and uveitis. The company
has its most advanced product candidate progressed into Phase I and II studies.

To advance its sustainable platform for ongoing biologics development, including a
pipeline of novel antibody fragments and the fully human single-chain antibody
framework technology, structures of scFv antibody fragments and their interaction
with target molecules are being investigated in molecular detail. A crystallization- and
structure-solving-pipeline is being implemented, that is integrated with facilities and
services of the University of Zürich and of the SLS. Thousands of crystallization
conditions are routinely screened at the nano-liter scale using state-of-the art robotic
systems including an automated incubation and imaging system (crystal Farm).
Diffraction data of crystals obtained are recorded at the SLS PX beamlines. Structure
determination is performed at ESBATech.




                  JUM@P ’09: Joint Users’ Meeting at PSI, October 12-13, 2009

				
DOCUMENT INFO